Abstract:Immunomodulatory agents blocking the PD-1/PD-L1 pathway have shown a new way to treat cancer. The explanation underlying the success of these agents may be the selective expression of PD-L1 with dominant immune-suppressive activities in the tumor microenvironment (TME), supporting a more favorable tumor response-to-toxicity ratio. However, despite the big success of these drugs, most patients with cancer show primary or acquired resistance, calling for the identification of new immune modulators in the TME. Using a genome-scale T-cell activity array in combination with bioinformatic analysis of human cancer databases, we identified Siglec-15 as a critical immune suppressor with broad upregulation on various cancer types and a potential target for cancer immunotherapy. Siglec-15 has unique molecular features compared with many other known checkpoint inhibitory ligands. It shows prominent expression on macrophages and cancer cells and a mutually exclusive expression with PD-L1, suggesting that it may be a critical immune evasion mechanism in PD-L1-negative patients. Interestingly, Siglec-15 has also been identified as a key regulator for osteoclast differentiation and may have potential implications in bone disorders not limited to osteoporosis. Here, we provide an overview of Siglec-15 biology, its role in cancer immune regulation, the preliminary and encouraging clinical data related to the first-in-class Siglec-15 targeting mAb, as well as many unsolved questions in this pathway. As a new player in the cancer immunotherapeutic arena, Siglec-15 may represent a novel class of immune inhibitors with tumor-associated expression and divergent mechanisms of action to PD-L1, with potential implications in anti-PD-1/PD-L1-resistant patients.

CD155 as an emerging target in tumor immunotherapy

TIGIT: A promising target to overcome the barrier of immunotherapy in hematological malignancies.

Targeting TIGIT for cancer immunotherapy: recent advances and future directions

Tumor Immune Checkpoints and Their Associated Inhibitors

The CD112R/CD112 Axis: a Breakthrough in Cancer Immunotherapy

Target therapy of TIGIT; a novel approach of immunotherapy for the treatment of colorectal cancer

Targeting immune checkpoints on tumor-associated macrophages in tumor immunotherapy.

CD155 Promotes the Progression of Cervical Cancer Cells Through AKT/mTOR and NF-κB Pathways

Immune Regulation and Immune Therapy in Melanoma: Review with Emphasis on CD155 Signalling

CD39 Transforming Cancer Therapy by Modulating Tumor Microenvironment

Blocking TIGIT/CD155 signalling reverses CD8+ T cell exhaustion and enhances the antitumor activity in cervical cancer

Research progress of CD155 in tumor

Siglec-15 as an Emerging Target for Next-generation Cancer Immunotherapy

Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts

Targeting the MHC-I endosomal-lysosomal trafficking pathway in cancer: From mechanism to immunotherapy

CD155 immunoregulation as a target for natural killer cell immunotherapy in glioblastoma

Targeting CD24/Siglec-10 signal pathway for cancer immunotherapy: recent advances and future directions

CD155 on Tumor Cells Drives Resistance to Immunotherapy by Inducing the Degradation of the Activating Receptor CD226 in CD8+ T Cells

Immune checkpoint blockade in the treatment of malignant tumor: current statue and future strategies

The immune checkpoint TIGIT/CD155 promotes the exhaustion of CD8 + T cells in TNBC through glucose metabolic reprogramming mediated by PI3K/AKT/mTOR signaling

CD8+ T cell-based cancer immunotherapy